Esophageal Cancer Risk Registry
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Gastroesophageal Reflux Disease , Gastrointestinal |
| Therapuetic Areas: | Gastroenterology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/10/2018 |
| Start Date: | June 1999 |
| End Date: | December 2050 |
| Contact: | Julie A Ward, BSN |
| Email: | wardj@upmc.edu |
| Phone: | 412-647-8583 |
The purpose of this study is to identify markers in the blood and tissue that could indicate
risk factors for the development and progression of esophagus cancer. This research aims to
collect medical history, blood, and tissue samples from patients who present with an
esophageal disorder. Identifying genetic and behavioral risk factors involved in the
development of esophageal cancer might allow for early detection and prevention. Survival and
an opportunity for a cure with esophageal cancer will depend greatly on the stage of
diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these
changes can sometimes be seen in normal tissues before the development of cancer. These
genetic (hereditary) changes can serve as tumor markers and can be detected using methods
that study changes in genetic material like DNA and RNA. The analysis of proteins can provide
additional information. By identifying changes in these molecules that are different or
altered in cancer, the investigators can use methods and tests for the detection of these
changes.
risk factors for the development and progression of esophagus cancer. This research aims to
collect medical history, blood, and tissue samples from patients who present with an
esophageal disorder. Identifying genetic and behavioral risk factors involved in the
development of esophageal cancer might allow for early detection and prevention. Survival and
an opportunity for a cure with esophageal cancer will depend greatly on the stage of
diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these
changes can sometimes be seen in normal tissues before the development of cancer. These
genetic (hereditary) changes can serve as tumor markers and can be detected using methods
that study changes in genetic material like DNA and RNA. The analysis of proteins can provide
additional information. By identifying changes in these molecules that are different or
altered in cancer, the investigators can use methods and tests for the detection of these
changes.
We will enroll patients with esophageal cancer, patients who are at risk for developing
esophageal cancer, and patients who have a non-cancerous esophageal disorder. All patients
will be asked to fill out a questionnaire about their general health and personal habits, and
about their relatives' medical history; this will be done during the preoperative clinic
visit. Prior to or at the time of the surgical procedure(s), and at the time of routine
follow-up visits, a sample of blood (about 3 tablespoons) will be drawn for research.
For patients undergoing an endoscopy after the normal biopsies are taken, several small
samples will be taken from the esophagus and stomach. These should total no more than eight
samples.
For patients undergoing an anti-reflux procedure with or without a Collis gastroplasty a
lymph node is normally removed. We will receive a small piece of that lymph node after the
pathologist has done the routine pathological evaluation of that node.
If the collis procedure is done, a new esophagus is formed and a small piece of stomach
tissue is discarded. We will study the ordinarily discarded tissue for the transformation of
cells from a normal to an abnormal state. The lymph node and stomach tissue will be collected
only once for the study.
For patients undergoing an esophagectomy (removal of the esophagus) or a staging procedure
(performed to determine size, exact location, and spread of tumor to nearby areas) prior to
an esophagectomy small pieces of tissue will be collected (from tumor, adjacent normal
esophageal lining, parts of lymph nodes, and any other tissues removed as a part of the
normal procedure) from your esophagectomy or staging specimens. This tissue will be collected
only once for the study. The samples collected will be analyzed for genetic changes in the
DNA and the RNA. The samples will be stored in a locked laboratory at the Hillman Cancer
Center Research Pavilion indefinitely or until the samples are depleted.
You may be contacted in the future to learn the results of any cancer screening tests you had
undergone and whether anyone else in your family had developed cancer. This information will
be entered in a computer data base for future study.
We may continue to collect additional biopsies during your routine clinical surveillance
endoscopies. Again biopsies for normal patient management will be obtained first.
esophageal cancer, and patients who have a non-cancerous esophageal disorder. All patients
will be asked to fill out a questionnaire about their general health and personal habits, and
about their relatives' medical history; this will be done during the preoperative clinic
visit. Prior to or at the time of the surgical procedure(s), and at the time of routine
follow-up visits, a sample of blood (about 3 tablespoons) will be drawn for research.
For patients undergoing an endoscopy after the normal biopsies are taken, several small
samples will be taken from the esophagus and stomach. These should total no more than eight
samples.
For patients undergoing an anti-reflux procedure with or without a Collis gastroplasty a
lymph node is normally removed. We will receive a small piece of that lymph node after the
pathologist has done the routine pathological evaluation of that node.
If the collis procedure is done, a new esophagus is formed and a small piece of stomach
tissue is discarded. We will study the ordinarily discarded tissue for the transformation of
cells from a normal to an abnormal state. The lymph node and stomach tissue will be collected
only once for the study.
For patients undergoing an esophagectomy (removal of the esophagus) or a staging procedure
(performed to determine size, exact location, and spread of tumor to nearby areas) prior to
an esophagectomy small pieces of tissue will be collected (from tumor, adjacent normal
esophageal lining, parts of lymph nodes, and any other tissues removed as a part of the
normal procedure) from your esophagectomy or staging specimens. This tissue will be collected
only once for the study. The samples collected will be analyzed for genetic changes in the
DNA and the RNA. The samples will be stored in a locked laboratory at the Hillman Cancer
Center Research Pavilion indefinitely or until the samples are depleted.
You may be contacted in the future to learn the results of any cancer screening tests you had
undergone and whether anyone else in your family had developed cancer. This information will
be entered in a computer data base for future study.
We may continue to collect additional biopsies during your routine clinical surveillance
endoscopies. Again biopsies for normal patient management will be obtained first.
Inclusion Criteria:
- Known or suspected esophageal or gastroesophageal junction malignancy
- Known Barrett's metaplasia
- Clinical management of symptomatic gastroesophageal reflux disease (GERD)
- Achalasia
- Hiatal hernia
Exclusion Criteria:
- Elevated pre-operative bloodwork will not have the additional biopsies taken.
- Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above,
and/or International Normalized Ratio (INR) of 1.8 or above will not have the
additional biopsies taken.
We found this trial at
1
site
Pittsburgh, Pennsylvania 15232
Principal Investigator: James Luketich, MD
Phone: 412-647-8583
Click here to add this to my saved trials
